Page 4 - Peter Schmid News Today

Researchers found that at 36 months, the estimated event-free survival was 84.5 and 76.8% in the pembrolizumab-chemotherapy and placebo-chemotherapy groups, respectively.

Trials have been launched in a bid to remedy long-running concerns that the system is prone to false alarms and misses cases in some women.

The addition of neoadjuvant pembrolizumab to chemotherapy reduced triple negative breast cancer recurrence by more than a third, trial results suggested.

The trial, named KEYNOTE-522, is the first phase III trial to demonstrate the benefit of adding immunotherapy to chemotherapy before patients receive

Around 15 of all breast cancers (more than 8,000 cases per year in the UK) are triple negative breast cancer.

Pembrolizumab cuts the risk of triple-negative breast cancer (TNBC) returning by 37 per cent in women who have already beaten the disease, a trial by Queen Mary University of London showed.

09.02.2022 - Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the publication of results from the Phase 3 KEYNOTE-522 trial in the Feb. 10, 2022 edition of the New England Journal of Medicine. Results showed that neoadjuvant ...

Keytruda treatment found to cut risk of aggressive cancer returning after surgery by more than a third

Mother-of-four Lesley Stephen, of Edinburgh, benefited from tucatinib and said she agreed to take the drug as part of a trial because I had nothing to lose after other treatments failed to work.

It was a clear, sunny, blue-sky day the day I learned I had breast cancer. The brutally unexpected so often seems to happen on such days.